Business Context and Reporting Period
Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 22, 2020
Reporting Period: Specific event date of April 22, 2020.
Key Financial Metrics
This filing is a Current Report on Form 8-K regarding a specific corporate event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material change reported is an intellectual property milestone rather than a financial one:
- Patent Allowance: The United States Patent and Trademark Office (USPTO) issued a formal notice of allowance for patent application serial no. 15/268,399.
- Patent Title: "IN VIVO PRIMING OF NATURAL KILLER CELLS".
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future performance, or specific risk factors beyond the standard context of a patent application. The primary focus is the successful progression of the Company's intellectual property portfolio.
Investor Verification Checklist
- Verify the status of patent application serial no. 15/268,399 on the USPTO database to confirm the allowance notice.
- Review the attached press release (Exhibit 99.1) for details on the commercial potential of the "IN VIVO PRIMING OF NATURAL KILLER CELLS" technology.
- Check subsequent filings (e.g., 10-Q or 10-K) for the impact of this patent on the Company's overall valuation or partnership opportunities.